XBiotech Statistics
Total Valuation
XBiotech has a market cap or net worth of $88.72 million. The enterprise value is -$74.77 million.
Important Dates
The next estimated earnings date is Tuesday, May 20, 2025, after market close.
| Earnings Date | May 20, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
XBiotech has 30.49 million shares outstanding. The number of shares has increased by 0.07% in one year.
| Current Share Class | 30.49M |
| Shares Outstanding | 30.49M |
| Shares Change (YoY) | +0.07% |
| Shares Change (QoQ) | -0.02% |
| Owned by Insiders (%) | 34.94% |
| Owned by Institutions (%) | 15.72% |
| Float | 19.84M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.46 |
| P/TBV Ratio | 0.48 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 11.56, with a Debt / Equity ratio of 0.06.
| Current Ratio | 11.56 |
| Quick Ratio | 11.49 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -52.63 |
Financial Efficiency
Return on equity (ROE) is -19.21% and return on invested capital (ROIC) is -12.91%.
| Return on Equity (ROE) | -19.21% |
| Return on Assets (ROA) | -12.47% |
| Return on Invested Capital (ROIC) | -12.91% |
| Return on Capital Employed (ROCE) | -23.08% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$418,815 |
| Employee Count | 92 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -32,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -64.98% in the last 52 weeks. The beta is 0.97, so XBiotech's price volatility has been similar to the market average.
| Beta (5Y) | 0.97 |
| 52-Week Price Change | -64.98% |
| 50-Day Moving Average | 3.12 |
| 200-Day Moving Average | 5.23 |
| Relative Strength Index (RSI) | 47.37 |
| Average Volume (20 Days) | 62,353 |
Short Selling Information
The latest short interest is 898,575, so 2.95% of the outstanding shares have been sold short.
| Short Interest | 898,575 |
| Short Previous Month | 697,589 |
| Short % of Shares Out | 2.95% |
| Short % of Float | 4.53% |
| Short Ratio (days to cover) | 13.35 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -42.47M |
| Pretax Income | -30.44M |
| Net Income | -38.53M |
| EBITDA | -40.73M |
| EBIT | -42.47M |
| Earnings Per Share (EPS) | -$1.26 |
Full Income StatementBalance Sheet
The company has $172.68 million in cash and $10.25 million in debt, giving a net cash position of $162.43 million or $5.33 per share.
| Cash & Cash Equivalents | 172.68M |
| Total Debt | 10.25M |
| Net Cash | 162.43M |
| Net Cash Per Share | $5.33 |
| Equity (Book Value) | 182.27M |
| Book Value Per Share | 5.98 |
| Working Capital | 159.46M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$30.96 million and capital expenditures -$1.30 million, giving a free cash flow of -$32.27 million.
| Operating Cash Flow | -30.96M |
| Capital Expenditures | -1.30M |
| Free Cash Flow | -32.27M |
| FCF Per Share | -$1.06 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |